Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer.

ABSTRACT:

Importance

Docetaxel has been a standard treatment for metastatic castration-resistant prostate cancer (mCRPC) since 2004. Cabazitaxel, a related taxane, was approved in 2010 for patients with mCRPC who had been previously treated with docetaxel. The comparative effectiveness of docetaxel rechallenge vs switching to cabazitaxel after prior docetaxel for mCRPC remains unclear.

Objective

To compare the clinical outcomes associated with docetaxel rechallenge vs cabazitaxel in patients with mCRPC who did not experience disease progression during prior administration of docetaxel in the mCRPC setting.

Design, setting, and participants

This retrospective cohort study was conducted in the nationwide Veterans Affairs health care system, using inverse probability of treatment

SUBMITTER: Barata PC 

PROVIDER: S-EPMC12811811 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature